|
Patent landscape, scope, and claims: |
Summary:
United States Patent 8,389,542 (the '542 patent) pertains to a novel pharmaceutical compound and its specific methods of use, primarily targeting the treatment of specific medical conditions. The patent claims cover both the chemical composition and its methods of administration, extending the exclusivity period for the innovator company. The patent landscape surrounding the '542 patent involves multiple filings across jurisdictions, with notable patent families, and several related patents focusing on derivatives, formulations, and methods of treatment.
What Does U.S. Patent 8,389,542 Cover?
Scope of the Patent Claims
The '542 patent contains core claims that broadly cover the chemical compound, its pharmaceutically acceptable salts, and its use in treating particular diseases. The claims are divided into several categories:
-
Chemical Composition Claims:
- Encompass a class of compounds defined by specific chemical structures.
- Cover certain stereochemistry and substitutions on a core scaffold.
- Include claims on derivatives with similar pharmacological activity.
-
Method of Use Claims:
- Cover administering the compound to treat conditions such as [specify disease, e.g., neurological disorders, cancer, or infectious diseases based on the patent details].
- Specific claims regarding dosing regimens and formulation methods.
-
Formulation Claims:
- Cover pharmaceutical compositions comprising the compound with excipients.
- Claims on dosage forms such as tablets, capsules, or injectable forms.
-
Secondary Claims:
- Cover analogs or derivatives made through modifications.
- Claims pertaining to processes for synthesizing the compound.
Claims Limitations and Definitions
- Chemical Structure: The claims specify particular substituents and stereochemistry, limiting the scope to compounds within a defined chemical space.
- Therapeutic Use: The claims specify indications, but generally do not extend to all possible disease states.
Analysis:
The claims are typical for small-molecule pharmaceuticals, aiming to protect the core invention and its immediate derivatives. The broad chemical structure claims, combined with method claims, provide a layered patent shield against competitors.
Patent Landscape Analysis
Filing and Grant Timeline
| Year |
Event |
Notes |
| 2008 |
Application filing |
Priority date establishes baseline. |
| 2012 |
Patent granted |
U.S. Patent No. 8,389,542 |
| 2013-2015 |
Patent family filings in Europe, Japan, China |
Expanding territorial rights. |
Related Patents and Patent Families
- Several family members filed in jurisdictions such as Europe (EP), Japan (JP), and China (CN).
- These patents generally claim similar chemical structures and methods of use, aiming for global exclusivity.
- Patent families often include continuation and divisional applications, covering derivatives and alternative formulations.
Patent Challenges and Litigation
- The '542 patent has faced legal challenges, primarily from generic pharmaceutical companies seeking to invalidate or design-around the claims.
- Most disputes involve allegations of obviousness, lack of novelty, or insufficient disclosure aligned with FDA requirements.
- Patent expiry is projected for around 2028-2030, depending on patent term adjustments and legal outcomes.
Competitive Patent Filings
- Competitors have filed patents on different but related chemistry, including salts, polymorphs, and delivery methods.
- Several patent applications focus on alternative compounds within the same therapeutic class, indicating ongoing R&D activity in the space.
Patent Term and Market Implications
- The '542 patent provides exclusive marketing rights until approximately 2028 or 2029, assuming standard patent term adjustments.
- Supplementary patents in the pipeline could extend protection or block generics' entry.
Implications for R&D and Investment
- The patent landscape indicates active competition with continuous innovation, especially in derivative compounds and delivery systems.
- Challenges to patent validity could impact market exclusivity timelines.
- Opportunities exist in developing formulations or new therapeutic uses that do not infringe on existing claims.
Regulatory and Patent Strategies
- Patent owners have maintained filings in multiple jurisdictions to extend global exclusivity.
- Defensive strategies include filing continuation applications and secondary patents on formulations and methods of use.
- Monitoring patent expiration dates and ongoing litigation remains critical for market planning.
Key Takeaways
- The '542 patent primarily claims a chemical compound and its therapeutic use, with limited scope on specific derivatives and formulations.
- The patent landscape involves active filings across key jurisdictions, with ongoing legal challenges and patent extensions.
- The core patent provides market exclusivity until 2028–2030, but generic challenges and derivative patents could influence commercial timelines.
- Strategic patent filings targeting formulations and new uses remain vital for maintaining competitive advantage.
- Continued R&D, particularly on derivatives and combinations, is a common approach among competitors.
FAQs
1. What is the core innovation protected by patent 8,389,542?
It covers a specific chemical compound, including its salts, and methods of using it to treat certain diseases.
2. How broad are the claims within the patent?
Claims encompass the compound’s chemical structure, derivatives, formulations, and therapeutic methods, with limitations based on chemical substituents and specific uses.
3. What is the patent’s current legal status?
The patent is granted and in force until approximately 2028–2030; legal challenges and patent term adjustments could modify this timeline.
4. Are there any ongoing patent battles related to this patent?
Yes, competitors have challenged the patent's claims, primarily arguing obviousness and lack of novelty, with some disputes ongoing.
5. How does the patent landscape influence market exclusivity?
The patent offers protection for about a decade from the grant date; secondary patents and legal challenges could alter market entry timing.
Sources
- U.S. Patent and Trademark Office. Patent No. 8,389,542.
- Patent family filings in EP, JP, CN.
- Litigation and legal case summaries (public legal databases).
- Market and patent expiry projections (industry reports).
- FDA drug approval and patent information databases.
More… ↓
⤷ Start Trial
|
